Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial

BACKGROUND: HER2 dual-blockade combined with aromatase inhibitors (AI) is a promising strategy to improve progression-free survival (PFS) in hormone receptor (HR) positive, metastatic breast cancer (MBC). Pyrotinib is a novel irreversible epidermal growth factor receptor/HER2 dual tyrosine kinase in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Main Authors: Wang, Changjun, Lin, Yan, Zhou, Yidong, Mao, Feng, Zhu, Hanjiang, Guan, Jinghong, Zhang, Xiaohui, Shen, Songjie, Huang, Xin, Chen, Chang, Yao, Ru, Zhao, Jialin, Sun, Qiang
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Study Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359576/
https://ncbi.nlm.nih.gov/pubmed/32660609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07143-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares